Asahi shares mark weekly slide after cyberattack halts production
CAMBRIDGE, Mass. - Vyome Therapeutics, Inc. has completed its previously announced merger with ReShape Lifesciences Inc. (Nasdaq:RSLS), according to a press release issued by the company. The combined entity will begin trading under the name Vyome Holdings, Inc. and the ticker symbol HIND when markets open on Friday, August 15, 2025. The stock currently trades at $13.59, within its 52-week range of $11.61 to $14.89.
Vyome, a clinical-stage healthcare company based in Cambridge, Massachusetts, focuses on immuno-inflammatory and rare diseases in U.S. and global markets. The company positions itself across what it calls the "US-India innovation corridor" to develop treatments for patients with immuno-inflammatory conditions.
The merger represents the culmination of a transaction that was previously disclosed to investors, though specific financial terms and operational details of the combination were not provided in the announcement.
Vyome describes itself as a healthcare platform that aims to deliver value to shareholders while maintaining global standards in quality and safety.
The information in this article is based on a company press release statement. As with any corporate merger, actual results may differ from anticipated outcomes, and the combined company will face integration challenges and market competition as it moves forward under its new identity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.